Global Embolization Market, by Product Type (Particles (Radioembolization Spheres, Drug-eluting Beads, Microspheres (or Bland's beads, without drug), and PVA particles (Polyvinyl Alcohol), Liquid Embolic, Plugs, and Coils), by Indication (Hemorrhage/Bleeding, Benign Prostatic Hyperplasia (BPH), Uterine Fibroid, Tumor (Malignant, including Liver (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa). According to a recent analysis released by Coherent Market Insights, the market is predicted to be worth US$ 1,433.6 million in 2020, with a CAGR of 8.1 percent over the forecast period (2020-2027).
Researchers and key players in the embolization market are focusing on developing innovative embolization products for the treatment of various chronic diseases such as tumors, hemorrhage, and others, which is expected to provide lucrative opportunities for market players to launch new products and expand their product portfolio and geographic footprint globally.
For example, Keystone Heart, LTD., a medical device firm, reported in October 2020 that its TriGUARD 3 Cerebral Embolic Protection (CEP) device has completed the first international commercial case. Pieter Stella, M.D., an assistant professor at UMC Utrecht's Medical Department of Cardiology, successfully completed transcatheter aortic valve implantation (TAVI) using the TriGUARD 3 device, which is meant to reduce the risk of brain injury during trans-catheter heart surgeries.
Embolization is a minimally invasive process in which embolic agents such as embolic coils, plugs, drug-eluting beads, and others are used to stop the blockage of specific blood arteries. GI bleeding, varicocele, cerebral aneurysm, malignancies (liver cancer and kidney cancer), and other conditions can all benefit from embolization operations. Furthermore, people with tumors including kidney cancer, liver cancer, and others are more likely to be impacted by COVID-19.